Open AccessP1154: STUDY ZILO‐301: A PHASE 3, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
Author(s) -
Yazji S.,
Hamburger S.,
Wang Y.,
Yavrom S.,
Pietrofeso A.,
Bliss R.,
Breitmeyer J. B.,
Dreyling M.,
Wang M.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847484.83317.ef
Subject(s) - ibrutinib , medicine , mantle cell lymphoma , phases of clinical research , population , oncology , clinical endpoint , refractory (planetary science) , placebo , rituximab , surrogate endpoint , clinical trial , lymphoma , leukemia , pathology , alternative medicine , chronic lymphocytic leukemia , physics , environmental health , astrobiology